


## TIE-2/VEGFR-2 kinase-IN-1

<b>Cat. No.:</b>	HY-112294		
<b>CAS No.:</b>	453590-24-4		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>11</sub> N <sub>3</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	241.25		
<b>Target:</b>	VEGFR; Tie		
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 5 mg/mL (20.73 mM; ultrasonic and warming and heat to 80°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	4.1451 mL	20.7254 mL	41.4508 mL
		5 mM	0.8290 mL	4.1451 mL	8.2902 mL
10 mM		0.4145 mL	2.0725 mL	4.1451 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 4 mg/mL (16.58 mM); Clear solution; Need ultrasonic  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 4 mg/mL (16.58 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Tie2
<b>In Vitro</b>	Angiopoietin 1 is a ligand for the endothelium-specific receptor tyrosine kinase, TIE-2 is a novel angiogenic factor <sup>[1]</sup> . Inhibition of TIE-2 is expected to serve to disrupt remodeling and maturation of new vasculature initiated by angiogenesis thereby disrupting the angiogenic process. Inhibition at the kinase domain binding site of VEGFR-2 would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis.

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Jerry Leroy Adams, et al. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors. Patent WO2003022852.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA